ReviewFrontiers in cellular and infection microbiology2025
The intersection of
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Advances inOncology letters · 2026Review
- Cuproplasia-associated LOXL2 cooperates withJournal of gastrointestinal oncology · 2026Article
- Therapeutic Potential of Polysaccharide-Modulated Gut Microbiota-Immune Axis in Gastrointestinal Cancers: Modern Insights From Traditional Pharmacy.Molecular nutrition & food research · 2026Review
- Exploring 14-3-3ζ: insights into its role in cancer mechanisms and future therapeutic applications.Hereditas · 2026Review
- Microbiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight.International journal of molecular sciences · 2026Review
- Tight junction proteins: Gatekeepers turned facilitators in the pathogenesis of gastric adenocarcinoma.World journal of gastrointestinal oncology · 2026Review
- Exploratory metabolomic analysis for identifying systemic signatures ofFrontiers in immunology · 2026Article
- Integrative management of gastric cardia cancer and precancerous lesions: prospects and mechanistic rationale for Banxia Xiexin Tang.Frontiers in pharmacology · 2026Review
- Review of Peptic Ulcer Disease: Insights from Pathophysiology, Mechanisms, Pharmacotherapy, Phytotherapy, and Case Reports.Drug design, development and therapy · 2026Review
- Patchouli alcohol suppressesFrontiers in pharmacology · 2026Article
- Integrated virulence-resistance profiling ofFrontiers in cellular and infection microbiology · 2026Article
- Upregulation of innate and adaptive immune mechanisms facilitating prevention of gastricFrontiers in immunology · 2026Article
- miR-136: A biomarker in the inflammation-cancer transformation of gastric cancer.World journal of gastrointestinal oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.